LRMR
Income statement / Annual
Last year (2023), Larimar Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Larimar Therapeutics, Inc.'s net income was -$36.95 M.
See Larimar Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$311,000.00 |
$272,000.00 |
$326,000.00 |
$155,000.00 |
$78,000.00 |
$261,000.00 |
$188,000.00 |
$212,000.00 |
$70,000.00 |
$0.00 |
| Gross Profit |
-$311,000.00 |
-$272,000.00 |
-$326,000.00 |
-$155,000.00 |
-$78,000.00 |
-$261,000.00 |
-$188,000.00 |
-$212,000.00 |
-$70,000.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$27.67 M
|
$24.25 M
|
$38.40 M
|
$31.41 M
|
$20.79 M
|
$49.53 M
|
$41.74 M
|
$39.77 M
|
$54.62 M
|
$27.39 M
|
| General & Administrative
Expenses |
$14.09 M
|
$12.28 M
|
$12.07 M
|
$11.40 M
|
$2.42 M
|
$1.52 M
|
$12.16 M
|
$18.29 M
|
$19.20 M
|
$8.14 M
|
| Selling & Marketing
Expenses |
$14.07 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$12.93 M
|
-$212,000.00
|
-$1.15 M
|
-$70,000.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$14.09 M
|
$12.28 M
|
$12.07 M
|
$11.40 M
|
$2.42 M
|
$12.93 M
|
$11.95 M
|
$17.14 M
|
$19.13 M
|
$8.14 M
|
| Other Expenses |
$0.00 |
$1.17 M |
-$171,000.00 |
$322,000.00 |
$82,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$41.76 M |
$36.53 M |
$50.47 M |
$42.80 M |
$23.21 M |
$62.46 M |
$53.69 M |
$56.91 M |
$73.74 M |
$35.53 M |
| Cost And Expenses |
$41.76 M |
$36.53 M |
$50.47 M |
$42.80 M |
$23.21 M |
$62.72 M |
$53.88 M |
$57.12 M |
$73.81 M |
$35.53 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.99 M |
$1.89 M |
$996,000.00 |
$894,000.00 |
$438,000.00 |
$28,000.00 |
| Interest Expense |
$0.00 |
-$318,000.00 |
$0.00 |
$0.00 |
-$1.77 M |
-$246,000.00 |
$971,000.00 |
$347,000.00 |
-$473,000.00 |
-$870,000.00 |
| Depreciation &
Amortization |
$311,000.00
|
$272,000.00
|
$326,000.00
|
$155,000.00
|
$78,000.00
|
$261,000.00
|
$188,000.00
|
$212,000.00
|
$70,000.00
|
$0.00
|
| EBITDA |
-$41.45 M
|
-$36.53 M
|
-$50.47 M
|
-$42.80 M
|
-$23.14 M
|
-$62.46 M
|
-$53.69 M
|
-$56.91 M
|
-$73.74 M
|
-$35.53 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$4.81 M
|
$1.17 M
|
-$171,000.00
|
$322,000.00
|
$82,000.00
|
-$246,000.00
|
$947,000.00
|
-$1.06 M
|
-$473,000.00
|
-$1.04 M
|
| Income Before Tax |
-$36.95 M |
-$35.36 M |
-$50.64 M |
-$42.48 M |
-$23.13 M |
-$62.97 M |
-$52.93 M |
-$58.18 M |
-$74.29 M |
-$36.57 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$1.17 M |
-$326,000.00 |
-$155,000.00 |
-$93,860.00 |
-$1.60 M |
-$900,000.00 |
-$300,000.00 |
-$946,000.00 |
$0.00 |
| Net Income |
-$36.95 M |
-$34.18 M |
-$50.31 M |
-$42.33 M |
-$23.13 M |
-$61.37 M |
-$52.03 M |
-$57.88 M |
-$74.29 M |
-$36.57 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.84 |
-1.33 |
-2.93 |
-3.56 |
-2.51 |
-22.85 |
-22.76 |
-25.44 |
-33.32 |
-15.14 |
| EPS Diluted |
-0.84 |
-1.33 |
-2.93 |
-3.56 |
-2.51 |
-22.85 |
-22.76 |
-25.44 |
-33.32 |
-15.14 |
| Weighted Average Shares
Out |
$43.90 M
|
$25.76 M
|
$17.16 M
|
$11.88 M
|
$9.21 M
|
$2.69 M
|
$2.29 M
|
$2.27 M
|
$2.23 M
|
$2.42 M
|
| Weighted Average Shares
Out Diluted |
$43.90 M
|
$25.76 M
|
$17.16 M
|
$11.88 M
|
$9.21 M
|
$2.69 M
|
$2.29 M
|
$2.27 M
|
$2.23 M
|
$2.42 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
